Follow-The-Filings

Security · featured owners

IONS Ionis Pharmaceuticals Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 4 Owners
  • Max 13.7%
  • $207M
  • 2 add 2 reduce 1 exit

IONS (Ionis Pharmaceuticals Inc.) is held in 4 featured 13F books as of 2026 Q2. Tweedy, Browne Co. is the largest tracked holder by portfolio weight (13.7%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 13.7% (Tweedy, Browne Co.) · not free-float ownership

  1. Tweedy, Browne Co. add 13.7%
  2. Cathie Wood add 0.15%
  3. Murray Stahl reduce 0.01%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Tweedy, Browne Co. 2026 Q2 13.7% Add +0.2% 2,280,311 $181M history
Cathie Wood - Ark Investment Management 2026 Q2 0.15% Add +4.2% 300,770 $24M history
Ron Baron - Bamco Inc. (Baron Capital) 2026 Q2 <0.01% Reduce −68.9% 14,000 $1M history
Murray Stahl - Horizon Kinetics Asset Management 2026 Q2 0.01% Reduce −4.6% 10,904 $865K history
Farallon Capital Management exited 2026 Q2 last 2026 Q1 <0.01% Exit 0.00% 4,800 $360K history

4 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 10 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q IONIS PHARMACEUTICALS, INC. 10-Q 06-30-2026 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.02,5.07,7.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 9 rows shown

Filed Form Detail Links
4 Period Aug 31, 2026 · 4 forms Filing Doc
4 Period Jul 30, 2026 Filing Doc
4 Period Jul 15, 2026 · 4 forms Filing Doc
4 Period Jul 7, 2026 · 3 forms Filing Doc
4 Period Jul 1, 2026 · 7 forms Filing Doc
4 Period Jun 26, 2026 · 3 forms Filing Doc
4 Period Jun 25, 2026 Filing Doc
4 Period Jun 24, 2026 Filing Doc
4 Period Jun 15, 2026 Filing Doc

Updated 6 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $787.65M $705.14M $943.71M
Gross profit * $778.51M $693.92M $927.8M
Gross margin * 98.8% 98.4% 98.3%
Net income -$366.29M -$453.9M -$381.39M
Net margin * -46.5% -64.4% -40.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $2.64B $2.62B $2.99B
Total non-current assets * $348.22M $383.38M $533.2M
Total assets $2.99B $3B $3.52B
Total current liabilities $448.09M $309.32M $781.57M
Total non-current liabilities * $2.16B $2.11B $2.25B
Total equity $386.69M $588.35M $489.09M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$307.51M -$500.95M -$268.58M
Cash from investing -$214.13M -$134.03M -$277.78M
Cash from financing $644.08M $478.06M $675.84M
Net change in cash $122.79M -$157.19M $130.18M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders